Cullinan Therapeutics
CGEM
15.63
-0.62
-3.82%
Cullinan Therapeutics
US · CGEM
#3243 by market cap
Listed 2021
15.63
-0.62
-3.82%
Live - 5344 symbols - heartbeat 23s ago
· 2026-10-08 09:16
Pre-market
15.00
-4.03%
After-hours
15.63
0.00%
- Market cap
- 1.01B
- P/E (TTM)i
- -5.03
- P/Bi
- 3.13
- EPSi
- -3.36
- Div yieldi
- 0.00%
- 52W posi
- 54%
Reader sentiment
Are you bullish or bearish on CGEM?
Anonymous reader poll. Unscientific, not investment advice.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
- Founded
- 2016
- CEO
- Mr. Nadim Ahmed
- Employees
- 109
- Headquarters
- Cambridge, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- cullinantherapeutics.com
Company profile
- Exchange
- US
- Symbol
- CGEM
- Market-cap rank
- #3243
- Listing date
- 2021-01-08
- Market cap
- 1.01B
- Float cap
- 751.60M
- Shares out
- 64.35M
- Float shares
- 48.09M
Sectors & themes
Quote time 2026-10-08 09:16:24 · For reference only, not investment advice and not tailored to your situation.